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Background: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
(CLIPPERS) was first described in 2010 by Pittock and colleagues. All reported patients presented with diplopia and
gait ataxia and had similar typical MRI findings with punctuate gadolinium enhancement of the pons. Alternative
diagnoses were excluded by means of laboratory, radiological and histological tests. All patients were successfully
treated with steroids. We present a case in which the steroid therapy was switched to long term
immunosuppressive therapy, leading to several severe side-effects, but sustained clinical improvement.
Case presentation: A 63-year-old male presented with sub-acute diplopia and progressive gait ataxia. During
admission his neurological condition worsened and he developed multiple cranial nerve deficits, paraparesis and
urine retention. MRI-findings were remarkable with punctuate enhancement with gadolinium of the pons.
Cerebrospinal fluid only showed elevated protein levels and all other additional investigations were normal. The
probable diagnosis of CLIPPERS was made and intravenous corticosteroids were administered. This led to rapid
clinical recovery and decreased enhancement on the MRI-scan. Long-term oral immunosuppressive therapy was
started. One-and-a-half year later our patient has no recurrence of neurological symptoms, however due to the side
effects of the immunosuppressive therapy he was readmitted several times.
Conclusion: CLIPPERS presents with distinctive clinical and MRI-findings and may be diagnosed after excluding
other differential diagnoses. Patients are treated with corticosteroids with good clinical results. Since short term
glucocorticoid treatment results into relapse of the disease, longer term immunosuppressive therapy appears to be
mandatory for sustained improvement, although accompanied by severe side effects.
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Chronic lymphocytic inflammation with pontine perivas-
cular enhancement responsive to steroids (CLIPPERS)
was first described in 2010 by Pittock et al. [1] They de-
scribed eight patients presenting with similar clinical
and MRI-findings: sub-acute diplopia, gait ataxia and
punctiform gadolinium enhancement “peppering” the
pons. As distance from the pons increased, lesions be-
came less numerous. Other accompanying clinical symp-
toms included dysartria, dysesthesia of the face and
finally paraparesis and urine retention. The main mani-
festations of CLIPPERS are summarized in Table 1.* Correspondence: j.wijntjes@slaz.nl
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reproduction in any medium, provided the orSince 2010, several new possible cases have been
published (Table 2). Despite extensive diagnostic work-
up so far, the pathogenesis had not been elucidated. An
immune-mediated process has been postulated on the
basis of the establishment of T-cell predominant infiltrates
of the affected brain lesions and radiologic resolution of
the lesions upon immunosuppressive treatment.
All patients described so far (Table 2) were treated with
intravenous and subsequent oral corticosteroids with
gradually improvement of the clinical condition. Unfortu-
nately, almost all patients relapsed following glucocortic-
oid tapering and required maintenance glucocorticoid or
other immunosuppressive therapy. We present this new
case of CLIPPERS to underline the importance of introdu-
cing maintenance immunosuppressive therapy afterl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Core features of CLIPPERS (adapted from Simon
et al.) [2]
Clinical:
- subacute progressive ataxia and diplopia
Radiological:
- numerous punctate or nodular enhancing lesions bilaterally within
one of the three following anatomical locations: pons, brachium
pontis (=middle cerebellar punducle), cerebellum
- individual radiological lesions are small but may coalesce to form
larger lesions
- lesions may occur in the spinal cord, basal ganglia or cerebral white
matter but should be decreasing density with increasing distance
from the pons.
Corticosteroid responsiveness:
- prompt and significant clinical and radiological response to
corticosteroids
Histopathological:
- white matter perivascular lymphohistiocytic infiltrate with or without
parenchymal extension.
- infiltrate contains predominantly CD3 + and CD20+ lymphocytes.
- absence of the following histopathological characteristics:
○ monoclonal or atypical lymphocyte population
○ necrotising granulomatomas or giant cells
○ histological features of vasculitis
Differential diagnosis should be excluded:
- CNS lymphoma, glioma, primary CNS vasculitis, paraneoplastic
syndrome, sarcoidosis, demyelinating disease, Behcet’s and Sjogren
disease, tuberculosis, neurolues, Whipple’s disease and histiocytosis.
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for side effects during this prolonged therapy.Case presentation
A 63-year-old male presented with a five week history
of double vision, rotational vertigo with tinnitus, pro-
gressive gait imbalance and apathy. One month earlier
he had undergone tibia osteotomy surgery because of
varus deformity. He used no medication. He had a his-
tory of alcohol abuse and did not smoke. He had no his-
tory of international traveling. There was no family
history of neurological disease.
Except from postsurgical findings at his right knee
general physical examination was normal. The blood
pressure was 130/70 mmHg, pulse rate 78/minute, and
he was afebrile. On initial neurological examination he
was alert and cognitive functions were normal. His
speech was dysarthric, chantering. Examination of the
cranial nerves revealed a right abducens nerve paresis
and an upbeat nystagmus. The pinprick sensation in the
V3 distribution of the trigeminal nerve was symmetric-
ally decreased. Other cranial nerve functions werenormal. Strength was normal in muscles of the arms and
legs and sensation was preserved. Vibration sense on
both legs was diminished. The arms and legs on both
sides showed atactic, dysmetric movements. Tendon re-
flexes were normal and the plantar reflexes were normal.
He had an impressive gait ataxia and he was unable to
walk without aid. His gait was further impaired due to
the recent surgery.
As he was known with alcohol abuse, Wernicke’s syn-
drome was firstly assumed and he was promptly treated
with intravenous thiamine.
However, the neurological condition of the patient fur-
ther deteriorated. He developed difficulties swallowing
and became incontinent for urine. His gait ataxia wors-
ened and a slight spastic paraparesis developed.
In this patient with progressive cranial nerve dysfunc-
tion with ocular signs, ataxia and pyramidal tract signs,
brain stem dysfunction with a variety of causes should
be considered. The broad differential diagnosis included
CNS lymphoma, primary CNS vasculitis, demyelinating
diseases, paraneoplastic syndromes, sarcoidosis, tubercu-
losis and neurolues. The diagnosis of Wernicke’s syn-
drome was rejected as the clinical picture deteriorated
and the pre-treatment thiamine level showed to be
118 nmol/L (normal range: 60–200 nmol/L).
MRI T2-weighted and fluid-attenuated inversion recov-
ery (FLAIR) images of the brain demonstrated distinct
hyperintensity abnormalities consisting of punctuate le-
sions in the pons, brachium pontis and cerebellum
(Figure 1A). The lesions were gadolinium enhancing but
had no significant mass effect.
Blood levels of C-reactive protein, ESR, Vit B12 and
Angiotensine Converting Enzyme levels were normal.
Liver parameters were normal except for a slightly ele-
vated gamma-GT of 65 U/L (reference <55 U/L). Thy-
roid functions were normal.
Antinuclear antibodies, double-stranded DNA anti-
bodies, extractable nuclear antigens, antineutrophil cyto-
plasmic antibodies and antineuronal antibodies (anti-Hu,
anti-Yo, anti-Ri, anti-Tr, anti-amphiphysine, anti-CV2
and anti-Ma2) were not detected.
Serologic tests on Syphilis, HIV, Borrelia Burgdorferi,
anti-DNase B and anti-streptolysine titer were negative.
Auramine staining and PCR for M.tuberculosis complex
DNA were negative.
Analysis of the cerebrospinal fluid showed a raised
protein level (protein 1.3 g/L, reference range 0.2–0.5)
and a slight pleiocytosis (6,0 E06, reference <5 E06). Red
cell count and glucose levels were normal. The IgG
index was marginally increased (0.62, reference range
0.3–0.6), no oligoclonal bands were found. Cytology
study reports showed normal amounts of lymphocytes,
granulocytes monocytes and erythrocytes. Malignant
cells were not detected.
Table 2 Summary of published CLIPPERS case reports; initial- and follow up therapy
Author Cases Biopsy Initial
treatment





Pittock et al. [1] 8 4 prednisone 1 patient: prednisone and methotrexate 144 no 6/8
1 patient: prednisone 25 (died) no
1 patient: prednisone and azathioprine 43 no
1 patient: prednisone and mitoxantrone 14 no
4 patients: prednisone 20, 7, 22 and 7 no
Simon et al. [2] 5 5 prednisone 1 patient: prednisone and methotrexate 12 no 5/5
2 patients: prednisone, azathioprine and
cylophosphamide
36, 72 no
1 patient: prednisone, mycophenolate and
cylophosphamide
64 no
1 patient: prednisone and cylophosphamide 100 no
Taieb et al. [3] 1 1 prednisone prednisone and rituximab 9 no unknown
Jones et al. [4] 2* 1* prednisone prednisone > 6 no 1/1
Sempere et al. [5] 1 - prednisone prednisone and methotrexate 6 no unknown
Duprez et al. [6] 1 - prednisone unknown > 3 unknown unknown
List et al. [7] 1 - prednisone prednisone and methotrexate > 3 no unknown
Limousin et al. [8] 1** 1** - - - - -
Gabilondo et al.[9] 1 - prednisone prednisone, immunoglobulins iv once and
azathioprine
9 no 1/1
Kastrup et al. [10] 3 3 2/3 prednisone 1 patient: prednisone and cyclophosphamide 17 no 3/3
1 patient: prednisone 15 no
1/3 dexamethason 1 patient: dexamethason and methotrexate 9 no
Biotti et al. [11] 1 - prednisone prednisone and azathioprine 7 no unknown
* in a 2nd described case, biopsy was initiated after failed initial prednisone therapy. PA results showed a low grade astrocytoma.
** this case report described a case in which biopsy was initiated after failed initial prednisone therapy. PA results showed a primary central nervous
system lymphoma.
*** decline when maintenance treatment was tried to stopped.
A B
Figure 1 Coronal FLAIR MRI images. A. demonstrates the
characteristic punctuate hyperintens lesions of the pons. B. shows
diminishing of the pons-hyperintensity after glucocorticoid
administration. The lesions were enhancing after gadolinium
administration on T1 weighted images (not shown).









ASAT 20 U/l 97 U/l < 35
ALAT 18 U/l 172 U/l < 45
Alkaline phosphatase 105 U/l 82 U/l < 120
Bilirubin 9 umol/l 14 umol/l <17








Leucocytes 7,9 E09/l 1,5 E09/l 4,0–10,0
Erythrocytes 4,54 E12/l 1,96 E12/l 4,50–5,50
Hemaglobin 8,6 mmol/l 3,9 mmol/l 8,5–11,0
Hematocrit 0,42 l/l 0,18 l/l 0,40–0,50
Thrombocytes 229 E09/l 9 E09/l 150–400
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all negative.
MRI of the spinal cord and CT scanning of the chest,
abdomen and pelvis showed no abnormalities. Total
body PET CT scanning was negative for malignancies.
On the base of the typical MRI findings and exclusion
of other possible diagnoses the diagnosis of CLIPPERS
was presumed. The patient was treated with 1000 mg
intravenous methylprednisolone daily for a period of
three days, followed by oral prednisolone 80 mg per day.
Within a week from starting treatment the symptoms
gradually improved and on MRI two weeks from starting
treatment the pontine lesions decreased in number and
intensity (Figure 1B).
Maintenance immunosupressive therapy by oral pred-
nisolone 80 mg per day was continued, adding metho-
trexate 2.5 mg weekly to the regimen as long-lasting
immunosuppressive therapy was probably needed.
However, the therapy was complicated in several ways.
Firstly, by the end of the first month of therapy our
patient developed diabetes mellitus and deep venous
thrombosis. Subsequently, severe liver function abnormal-
ities developed after methotrexate was started (Table 3).
Therefore, this drug was substituted by azathioprine in a
step up dosage regimen up to 100 mg daily. Hereafter, a
severe and long-lasting pancytopenia developed (Table 3).
Bone marrow analysis showed hyperplastic erythropoiesis
and hypoplastic granulopoiesis compatible with a side
effect of the immunosuppressive therapy. The azathio-
prine was therefore stopped and prednisone 20 mg per
day was continued.
After recovering from the pancytopenia, mycofeno-
laatmofetil was added starting at 500 mg daily and in
increased dosage to 1000 mg bid. During this whole epi-
sode prednisone treatment was maintained at a dosage
of 20 mg daily. A severe intercurrent herpes infection
was treated with intravenous valcyclovir.
After a course of 18 months, our patient has not had
any relapse of his neurological deficits. There were no cra-
nial nerve deficits, no pareses and his gait was normal.
Discussion
We made the diagnosis of CLIPPERS combining the
clinical and typical MRI findings only after exclusion of
other possible diagnoses. We choose not to perform a
biopsy because of the localization of the abnormalities
and because the imaging results and clinical presentation
were very similar to the patients described by Pittock
et al. [1].
In most of previously published studies it was men-
tioned that discontinuation of steroid treatment led to a
clinical relapse (Table 2). Mean follow up time of all
published reports so far was 28 months (3–144 months),
and no successful steroid discontinuation was reported.It is known that induction of remission by using
glucocorticosteroids followed by maintenance glucocor-
ticosteroid combining other immunosuppressive therapy
in autoimmune diseases such as vasculitides should be
continued for at least 2–5 years [12,13]. Since CLIPPERS
has comparable pathologic features as in vasculitides
consisting of perivascular lymphocytic infiltrate, it seems
likely that tapering of maintenance therapy should be
proposed only after 2–5 years of treatment guided by
clinical monitoring and follow up MRI.
Finally we emphasize that in clinical practice one must
pay attention to the adverse events, as described in our
case. We recommend tapering immunosuppressive ther-
apy in conjunction with frequent clinical monitoring and
imaging, thus enabling us to treat any further relapse on
time. Our findings support the need for further follow
up studies to determine the duration of treatment.Conclusion
CLIPPERS presents with distinctive clinical and MRI-
findings and can be diagnosed after exclusion other
differential diagnoses [1,3]. Our patient confirmed the
appropriateness of the initiation of treatment without
histopathological confirmation.
A favourable clinical response to corticoid treatment
lends further support to the diagnosis of CLIPPERS. We
stress that careful clinical and laboratory monitoring is
warranted because of the side effects of longstanding
glucocorticosteroid and additional immunosuppressive
therapy. Follow-up studies to determine the duration of
treatment are necessary.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Series Editor of this journal.
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